Phase 2 study of zolbetuximab plus mFOLFOX6 in claudin 18.2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ): ILUSTRO cohort 2.

被引：6

作者：

Klempner, Samuel J.

Lee, Keun-Wook

Metges, Jean-Philippe

Catenacci, Daniel V. T.

Loupakis, Fotios

Ilson, David H.

Shah, Manish A.

Shitara, Kohei

Arozullah, Ahsan

Park, Jung Wook

Raizer, Jeffrey J.

Bang, Yung-Jue

机构：

[1] Massachusetts Gen Hosp, Boston, MA 02114 USA

[2] Seoul Natl Univ, Bundang Hosp, Coll Med, Seongnam, South Korea

[3] Hop Morvan, Ctr Hosp Reg Univ Brest, Brest, France

[4] Univ Chicago, Gastrointestinal Oncol Program, Chicago, IL 60637 USA

[5] Univ Azienda Osped Univ Pisana, Pisa, Italy

[6] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[7] Weill Cornell Med Coll, New York, NY USA

[8] Natl Canc Ctr Hosp East, Dept Gastrointestinal Oncol, Kashiwa, Chiba, Japan

[9] Astellas Pharma Global Dev Inc, Northbrook, IL USA

[10] Seoul Natl Univ, Coll Med, Seoul, South Korea

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.e16063

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e16063

引用

页数：3

共 50 条

[31] Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study
Shah, Manish A.
Starodub, Alexander
Sharma, Sunil
Berlin, Jordan
Patel, Manish
Wainberg, Zev A.
Chaves, Jorge
Gordon, Michael
Windsor, Kevin
Brachmann, Carrie Baker
Huang, Xi
Vosganian, Greg
Maltzman, Julia D.
Smith, Victoria
Silverman, Jeffrey A.
Lenz, Heinz-Josef
Bendell, Johanna C.
CLINICAL CANCER RESEARCH, 2018, 24 (16) : 3829 - 3837
[32] Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab plus CAPOX as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2L, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
Lordick, F.
Shah, M. A.
Shitara, K.
Ajani, J. A.
Bang, Y-J.
Enzinger, P. C.
Ilson, D. H.
van Cutsem, E.
Gallego Plazas, J.
Huang, J.
Shen, L.
Oh, S. C.
Sunpaweravong, P.
Soo, H. H. F.
Turk, H. M.
Park, J. W.
Moran, D.
Bhattacharya, P.
Cao, Y. J.
Xu, R-H.
ANNALS OF ONCOLOGY, 2023, 34 : S1524 - S1524
[33] Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma
Shitara, Kohei
Xu, Rui-Hua
Ajani, Jaffer A.
Moran, Diarmuid
Guerrero, Abraham
Li, Ran
Pavese, Janet
Matsangou, Maria
Bhattacharya, Pranob
Ueno, Yoko
Wang, Xuewei
Shah, Manish A.
GASTRIC CANCER, 2024, 27 (05) : 1058 - 1068
[34] Prevalence of claudin-18 isoform 2 (CLDN18.2) positivity in locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mg/GEJ) adenocarcinoma in patients (pts) in the Asia region: Phase III SPOTLIGHT and GLOW studies
Bang, Y-J.
Shen, L.
Kang, Y-K.
Chao, Y.
Soo, H. H. F.
Sunpaweravong, P.
Moran, D.
Guerrero, A.
Li, R.
Pavese, J.
Matsangou, M.
Bhattacharya, P.
Shitara, K.
Xu, R-H.
ANNALS OF ONCOLOGY, 2023, 34 : S1527 - S1528
[35] Phase 1b/2 study of margetuximab (M) plus pembrolizumab (P) in advanced HER2+gastroesophageal junction (GEJ) or gastric (G) adenocarcinoma (GEA).
Catenacci, Daniel V. T.
Park, Haeseong
Lockhart, A. Craig
Gold, Philip Jordan
Enzinger, Peter C.
Nordstrom, Jeffrey L.
Hong, Sam
Hochster, Howard S.
Kelly, Ronan Joseph
Uronis, Hope Elizabeth
Bendell, Johanna C.
Oh, Sang Cheul
Park, Se Hoon
Kim, Yeul Hong
Kang, Yoon-Koo
Lee, Keun-Wook
Ng, Matthew C. H.
Wigginton, Jon M.
Davidson-Moncada, Jan Kenneth
Bang, Yung-Jue
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
[36] Health-related quality of life (hrqol) in patients with claudin18 isoform 2-positive (CLDN18.2+) locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mg/GEJ) adenocarcinoma: Results from SPOTLIGHT and
Lordick, F.
Van Cutsem, E.
Shitara, K.
Xu, R-H.
Ajani, J. A.
Shah, M. A.
Oh, M.
Ganguli, A.
Rhoten, S.
Bhattacharya, P.
Matsangou, M.
Park, J. W.
Kang, Y-K.
ANNALS OF ONCOLOGY, 2023, 34 : S860 - S861
[37] Management of nausea and vomiting (N/V) following first-line (1L) zolbetuximab plus chemotherapy treatment in claudin-18.2 (CLDN18.2)+, HER2-, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Analysis from the phase 3 SPOTLIGHT and GLOW studies.
Shitara, Kohei
Pophale, Rupesh
Matsangou, Maria
Park, Jung Wook
Oh, Mok
Bhattacharya, Pranob P.
Ranganath, Radhika
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 372 - 372
[38] Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line therapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma
Xu, Rui-hua
Arkenau, Hendrik-Tobias
Bang, Yung-Jue
Denlinger, Crystal S.
Kato, Ken
Tabernero, Josep
Wang, Jin
Li, Jiang
Castro, Henry
Moehler, Markus H.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[39] Zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in first-line treatment of claudin 18.2-positive metastatic pancreatic cancer (mPC): Phase 2, open-label, randomized study
Park, Wungki
O'Reilly, Eileen Mary
Furuse, Junji
Li, Chung-Pin
Oh, Do-Youn
Garcia-Carbonero, Rocio
Roth, Gael
Lee, Ho-Jin
Kunieda, Futoshi
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[40] A phase II study of capecitabine-oxaliplatin and cetuximab in patients (pts) with advanced/metastatic gastric cancer (G) or gastroesophageal junction (GEJ) adenocarcinoma
Iqbal, Syma
El-Khoueiry, Anthony B.
Yang, Dongyun
Paez, David
Duddalwar, Vinay
Zhang, Wu
Agafitei, Raluca Dana
Lujan, Ramona
Cole, Sarah
Ning, Yan
El-Khoueiry, Rita
Loupakis, Fotios
Wakatsuki, Takeru
Lenz, Heinz-Josef
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)

← 1 2 3 4 5 →